Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew T. Kuykendall, David Sallman, Manish Patel, Don A. Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masarova, Gina Keiffer, Amit Verma, Neha Bhagwat, Diane Heiser, Sunhee Ro, Wan-Jen Hong, Omar Abdel-Wahab, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 3215.

https://doi.org/10.1182/blood-2024-198495

Published: 2024

Journal Articles

A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies

Michael T. Tees, David A. Bond, Nadia Khan, Farrukh T. Awan, Qiming Xu, Hui Zhang, Gladys Brown, Jennifer A. Woyach, Manish Patel

Blood (2024) 144 (Supplement 1): 4422.1.

https://doi.org/10.1182/blood-2024-194009

Published: 2024

Journal Articles

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C Coombs, Nirav N. Shah, William G. Wierda, Manish Patel, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Narasimha Marella, Caleb Ho, Samuel McNeely, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2023-181090

Published: 2023

Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Blood (2023) 142 (Supplement 1): 4463.

https://doi.org/10.1182/blood-2023-179872

Published: 2023

Journal Articles

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2023-181108

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2023-180048

Published: 2023

Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 325.

https://doi.org/10.1182/blood-2023-185852

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 3026.

https://doi.org/10.1182/blood-2023-181309

Published: 2023

Journal Articles

Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis

Tanya Burton, Kejal Parikh, Manish Patel, Kevin Sundquist, Lincy S. Lal, Ronda Copher, Aaron T. Gerds, MD MS

Blood (2019) 134 (Supplement_1): 4750.

https://doi.org/10.1182/blood-2019-124651

Published: 2019

Journal Articles

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Ian W. Flinn, Susan O’Brien, Brad Kahl, Manish Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey Jones, Jan A. Burger, Nitin Jain, Virginia M. Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven Horwitz

Blood (2018) 131 (8): 877–887.

https://doi.org/10.1182/blood-2017-05-786566

Published: 2018

Includes: Supplemental data

Journal Articles

Retrospective Study of Hematologic Complications in Vascular Malformation Patients with Localized Intravascular Coagulopathy Undergoing Surgical Intervention

Kiersten Ricci, MD, Carol Chute, CNP, Adrienne Hammill, MD PhD, Roshni Dasgupta, MD, Manish Patel, DO, Charles Myer IV, MD

Blood (2017) 130 (Supplement 1): 3693.

https://doi.org/10.1182/blood.V130.Suppl_1.3693.3693

Published: 2017

Journal Articles

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

Manish Patel, Paul Hamlin, MD, Donald K Strickland, MD, Anjali Pandey, PhD, Greg Coffey, PhD, Janet M Leeds, PhD, Gallia G. Levy, MD PhD, John T. Curnutte, MDPhD, Nina Wagner-Johnston, Ian W. Flinn, MD

Blood (2014) 124 (21): 3103.

https://doi.org/10.1182/blood.V124.21.3103.3103

Published: 2014

Journal Articles

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Susan O'Brien, Manish Patel, Brad S. Kahl, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Pierluigi Porcu, MD, Jennifer Sweeney, Kerstin Allen, MA, Kerrie Faia, MS, Howard M. Stern, MD PhD, Patrick Kelly, MD, Ian Flinn

Blood (2014) 124 (21): 3334.

https://doi.org/10.1182/blood.V124.21.3334.3334

Published: 2014

Journal Articles

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

Ian Flinn, Yasuhiro Oki, MD, Manish Patel, Steven M. Horwitz, MD, Francine M. Foss, MD, Jennifer Sweeney, Kerstin Allen, MA, Mark Douglas, MS, Lori Steelman, Joi Dunbar, PharmD, Howard M. Stern, MD PhD, Patrick Kelly, MD, Brad Kahl, MD

Blood (2014) 124 (21): 802.

https://doi.org/10.1182/blood.V124.21.802.802

Published: 2014

Journal Articles

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Blood (2014) 124 (21): 115.

https://doi.org/10.1182/blood.V124.21.115.115

Published: 2014

Journal Articles

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Michael Savona, MD, Martin Gutierrez, MD, Mark Lanasa, MD, PhD, Changchun Deng, MD, PhD, John Kuhn, PharmD, Lauren Sade, Hari Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Manish Patel, MD

Blood (2013) 122 (21): 4373.

https://doi.org/10.1182/blood.V122.21.4373.4373

Published: 2013

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Gilles Andre Salles, MD, PhD, Myron S. Czuczman, MD, Sarit E. Assouline, MD, Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, Manish Patel, MD, Randeep Sangha, Herve Tilly, MD, Ranjana Advani, MD, Olivier Casasnovas, MD, Oliver W. Press, MD, PhD, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Franck Morschhauser

Blood (2013) 122 (21): 4400.

https://doi.org/10.1182/blood.V122.21.4400.4400

Published: 2013

Journal Articles

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Ian Flinn, MD, PhD, Manish Patel, MD, Brad S. Kahl, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Yasuhiro Oki, MD, Pierluigi Porcu, MD, Jennifer Sweeney, BS, Kerstin Allen, MA, Kerrie Faia, MS, Patricia Harris, MPH, Joi Dunbar, PharmD, Howard M. Stern, M.D., Ph.D., Patrick Kelly, MD, Susan O'Brien, MD

Blood (2013) 122 (21): 677.

https://doi.org/10.1182/blood.V122.21.677.677

Published: 2013

Journal Articles

Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies

Joi Dunbar, PharmD, Jylle Nevejans, Charlotte McKee, MD, Kerrie Faia, MS, Jan Jaap van Lier, MD, Peter Pruim, MSc, Janet Stegehuis, PhD, Sue Zhao, MS, Brad S. Kahl, M.D., Steven M. Horwitz, MD, Manish Patel, MD, Anas Younes, MD, Ian W. Flinn, MD, PhD

Blood (2012) 120 (21): 4853.

https://doi.org/10.1182/blood.V120.21.4853.4853

Published: 2012

Journal Articles

Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

Ian W. Flinn, MD, PhD, Steven M. Horwitz, MD, Manish Patel, MD, Anas Younes, MD, James R. Porter, PhD, Jennifer Sweeney, Kerstin Allen, MA, Patrick Kelly, MD, Brad S. Kahl, M.D.

Blood (2012) 120 (21): 3663.

https://doi.org/10.1182/blood.V120.21.3663.3663

Published: 2012

NARROW

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Retrospective Study of Hematologic Complications in Vascular Malformation Patients with Localized Intravascular Coagulopathy Undergoing Surgical Intervention

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies

Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only